Literature DB >> 29663169

Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer.

Koichi Sawaki1, Mitsuro Kanda2, Takashi Miwa1, Shinichi Umeda1, Haruyoshi Tanaka1, Chie Tanaka1, Daisuke Kobayashi1, Masaya Suenaga1, Norifumi Hattori1, Masamichi Hayashi1, Suguru Yamada1, Goro Nakayama1, Michitaka Fujiwara1, Yasuhiro Kodera1.   

Abstract

BACKGROUND: Although peritoneal metastasis is a serious concern in patients with gastric cancer, no acceptable and specific biomarker is available. We aimed to identify a candidate biomarker to predict peritoneal metastasis of gastric cancer.
METHODS: Metastatic pathway-specific transcriptome analysis was conducted by comparison of patient groups with no recurrence and with peritoneal, hepatic, and nodal recurrence. Fifteen cell lines and 262 pairs of surgically resected gastric tissues were subjected to messenger RNA (mRNA) expression analysis. Polymerase chain reaction array analysis was performed to explore coordinately expressed cancer-related genes. To evaluate the in situ protein localization and expression patterns, immunohistochemical staining was performed.
RESULTS: From transcriptome data, troponin I2 (TNNI2) was identified as a candidate molecule specifically overexpressed in gastric cancer prone to peritoneal metastasis. TNNI2 mRNA was expressed at differential levels, independent of differentiated phenotype of cell lines. Epithelial to mesenchymal transition-related genes, tumor inhibitor of metalloproteinase 1 (TIMP1), and vacuolar protein sorting 13 homolog A (VPS13A) were expressed with TNNI2 at correlation coefficient > 0.7. The optimal cutoff of TNNI2 expression was determined as 0.00017. High TNNI2 expression was significantly and specifically associated with peritoneal metastasis and served as an independent risk marker for peritoneal recurrence after curative gastrectomy. Prevalence of peritoneal recurrence increased in parallel with staining intensity of TNNI2.
CONCLUSIONS: TNNI2 expression in gastric tissues may serve as a specific biomarker for prediction of peritoneal metastasis of gastric cancer and contribute to improvement of patient management.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29663169     DOI: 10.1245/s10434-018-6480-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  Gamma-aminobutyric Acid Type A Receptor Subunit Delta as a Potential Therapeutic Target in Gastric Cancer.

Authors:  Koichi Sawaki; Mitsuro Kanda; Hayato Baba; Yoshikuni Inokawa; Norifumi Hattori; Masamichi Hayashi; Chie Tanaka; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2022-09-20       Impact factor: 4.339

2.  Low expression of developing brain homeobox 2 (Dbx2) may serve as a biomarker to predict poor prognosis in endometrial cancer.

Authors:  Xinlu Zhang; Yaping Wang; Shujun Zhao; Qiaohong Qin; Min Zhang; Yi Jiang; Hai Zhu; Hongyu Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 3.  Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer.

Authors:  Masahiro Sasahara; Mitsuro Kanda; Yasuhiro Kodera
Journal:  Histol Histopathol       Date:  2021-03-09       Impact factor: 2.303

4.  Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.

Authors:  In-Seob Lee; Heonyi Lee; Hoon Hur; Mitsuro Kanda; Jeong-Hwan Yook; Byung-Sik Kim; Yanghee Woo; Yasuhiro Kodera; Kwangsoo Kim; Ajay Goel
Journal:  Clin Cancer Res       Date:  2021-02-08       Impact factor: 13.801

5.  Slow skeletal muscle troponin T, titin and myosin light chain 3 are candidate prognostic biomarkers for Ewing's sarcoma.

Authors:  Yajun Deng; Qiqi Xie; Guangzhi Zhang; Shaoping Li; Zuolong Wu; Zhanjun Ma; Xuegang He; Yicheng Gao; Yonggang Wang; Xuewen Kang; Jing Wang
Journal:  Oncol Lett       Date:  2019-11-04       Impact factor: 2.967

6.  Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram.

Authors:  Dexin Chen; Zhangyuanzhu Liu; Wenju Liu; Meiting Fu; Wei Jiang; Shuoyu Xu; Guangxing Wang; Feng Chen; Jianping Lu; Hao Chen; Xiaoyu Dong; Guoxin Li; Gang Chen; Shuangmu Zhuo; Jun Yan
Journal:  Nat Commun       Date:  2021-01-08       Impact factor: 14.919

7.  Differential DNA Methylation in Prostate Tumors from Puerto Rican Men.

Authors:  Gilberto Ruiz-Deya; Jaime Matta; Jarline Encarnación-Medina; Carmen Ortiz-Sanchéz; Julie Dutil; Ryan Putney; Anders Berglund; Jasreman Dhillon; Youngchul Kim; Jong Y Park
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

8.  SYT8 promotes pancreatic cancer progression via the TNNI2/ERRα/SIRT1 signaling pathway.

Authors:  Zhiping Fu; Xing Liang; Ligang Shi; Liang Tang; Danlei Chen; Anan Liu; Chenghao Shao
Journal:  Cell Death Discov       Date:  2021-12-14

9.  Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study.

Authors:  Donglang Jiang; Xing Chen; Zhiwen You; Hao Wang; Xiaoyun Zhang; Xiuming Li; Shuhua Ren; Qi Huang; Fengchun Hua; Yihui Guan; Jun Zhao; Fang Xie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-23       Impact factor: 9.236

10.  Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer.

Authors:  Weihua Li; Lei Guo; Wanxiangfu Tang; Yutong Ma; Xiaonan Wang; Yang Shao; Hong Zhao; Jianming Ying
Journal:  Clin Epigenetics       Date:  2021-06-09       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.